Amyotrophic Lateral Sclerosis — A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
Citation(s)
A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS)